Gain Therapeutics (GANX) Price & Analysis

Compare

375 Followers

GANX Stock Chart & Stats

$3.14

-$0.01(-0.44%)

At close: Jan 08 4:00 PM EST

$3.14

-$0.01(-0.44%)

Day’s Range― - ―

52-Week Range$1.41 - $3.40

Previous CloseN/A

Volume74.47K

Average Volume (3M)1.04M

Market Cap

$113.35M

Enterprise Value$53.74M

Total Cash (Recent Filing)$8.81M

Total Debt (Recent Filing)$180.94K

Price to Earnings (P/E)―

Beta1.53

Next Earnings

Mar 19, 2026

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding36,097,534

10 Day Avg. Volume1,074,251

30 Day Avg. Volume1,038,321

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)6.73

Price to Sales (P/S)0.00

P/FCF Ratio-2.62

Enterprise Value/Market Cap0.47

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-10.77

Enterprise Value/Ebitda-3.09

Forecast

1Y Price Target

$6.80

Price Target Upside116.56% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.65

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressThe P1b trial completed enrollment above the 15-patient target and received approval to extend dosing for up to 12 months, allowing for longer treatment assessment.

Drug EfficacyGT-02287 shows potential in reducing toxic alpha-synuclein levels, which are linked to neurodegenerative diseases like Parkinson's.

Safety ProfileGT-02287 was generally well tolerated, with no treatment-emergent serious adverse events and no protocol changes recommended after two independent data monitoring committee reviews.

Bears Say

Clinical Endpoint VariabilityThe clinical endpoints shown for individual patients were, as expected, very noisy.

Gain Therapeutics News

Gain Therapeutics presents data on GT-02287

Gain Therapeutics (GANX) announced a poster presentation was made at the Society for Neuroscience annual meeting, Neuroscience 2025,...

10d ago

GANX

Gain Therapeutics reports Q3 EPS (15c), consensus (15c)

“We are encouraged by the progress made during the third quarter of 2025 and remain on track to...

18d ago

GANX

Gain Therapeutics Announces New Stock Offering Program

The latest announcement is out from Gain Therapeutics ( ($GANX) ). Gain Therapeutics, Inc., a company involved in...

1d ago

GANX

Buy Rating for Gain Therapeutics: Promising Innovations in Disease Treatment

BTIG analyst Thomas Shrader has maintained their bullish stance on GANX stock, giving a Buy rating on November...

9d ago

GANX

Positive Outlook for Gain Therapeutics: Promising Clinical Trial Results and Stable Financial Health Drive Buy Rating

BTIG analyst Thomas Shrader has maintained their bullish stance on GANX stock, giving a Buy rating on November...

14d ago

GANX

Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Drive Buy Rating

Gain Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

16d ago

GANX

Gain Therapeutics Reports Continued Progress Amid Financial Challenges

Gain Therapeutics, Inc. ( ($GANX) ) has released its Q3 earnings. Here is a breakdown of the information...

17d ago

GANX

Gain Therapeutics, Inc. (GANX) Q3 Earnings Cheat Sheet

Gain Therapeutics, Inc. (GANX) is scheduled to report 3rd quarter earnings on 11/07/2025. Regarding Q3 estimates, Wall Street...

25d ago

GANX

Gain Therapeutics Advances Parkinson’s Treatment with GT-02287 Study

Gain Therapeutics, Inc. (($GANX)) announced an update on their ongoing clinical study. Gain Therapeutics, Inc. is conducting a...

1M ago

GANX

Unusually active option classes on open October 22nd

Unusual total active option classes on open include: Hain Celestial (HAIN), 1 800 Flowers (FLWS), Gain Therapeutics (GANX),...

1M ago

Buy Rating for Gain Therapeutics: Promising Potential of GT-02287 in Parkinson’s Treatment

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Gain Therapeutics, retaining the price target of...

1M ago

GANX

Gain Therapeutics price target lowered to $5 from $9 at BTIG

BTIG lowered the firm’s price target on Gain Therapeutics (GANX) to $5 from $9 and keeps a Buy...

1M ago

GANX

Eric Richman Resigns from Gain Therapeutics Board

Gain Therapeutics ( ($GANX) ) has issued an announcement. On October 6, 2025, Eric Richman resigned from Gain...

2M ago

GANX

Gain Therapeutics price target raised to $7 from $5 at Maxim

Maxim raised the firm’s price target on Gain Therapeutics (GANX) to $7 from $5 and keeps a Buy...

2M ago

GANX

GANX FAQ

What was Gain Therapeutics’s price range in the past 12 months?

Gain Therapeutics lowest stock price was $1.41 and its highest was $3.40 in the past 12 months.

What is Gain Therapeutics’s market cap?

Gain Therapeutics’s market cap is $113.35M.

When is Gain Therapeutics’s upcoming earnings report date?

Gain Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 109 days.

How were Gain Therapeutics’s earnings last quarter?

Gain Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.161 by $0.011.

Is Gain Therapeutics overvalued?

According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gain Therapeutics pay dividends?

Gain Therapeutics does not currently pay dividends.

What is Gain Therapeutics’s EPS estimate?

Gain Therapeutics’s EPS estimate is -0.14.

How many shares outstanding does Gain Therapeutics have?

Gain Therapeutics has 36,097,534 shares outstanding.

What happened to Gain Therapeutics’s price movement after its last earnings report?

Gain Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.161. Following the earnings report the stock price went up 10.075%.

Which hedge fund is a major shareholder of Gain Therapeutics?

Currently, no hedge funds are holding shares in GANX

Gain Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-261.72%

Trailing 12-Months

Asset Growth

-23.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Gain Therapeutics

Gain Therapeutics, Inc. (GANX) is a biotechnology company operating in the healthcare sector, focusing on discovering and developing novel therapies to treat rare genetic disorders and neurological diseases. The company utilizes its proprietary SEE-Tx platform to identify and optimize allosteric binding sites on proteins, which can be targeted to restore normal function in misfolded proteins, a common cause of many serious diseases.

Gain Therapeutics (GANX) Earnings & Revenues

Historic Earnings Reports

GANX Stock 12 Month Forecast

Average Price Target

$6.80

▲(116.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.96,2.4246153846153846,2.8892307692307693,3.3538461538461535,3.8184615384615386,4.283076923076923,4.747692307692308,5.212307692307692,5.676923076923076,6.141538461538461,6.606153846153846,7.070769230769231,7.535384615384615,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.96,2.332307692307692,2.7046153846153844,3.0769230769230766,3.449230769230769,3.821538461538461,4.193846153846154,4.566153846153846,4.938461538461539,5.31076923076923,5.683076923076923,6.055384615384615,6.427692307692308,{"y":6.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.96,2.193846153846154,2.4276923076923076,2.6615384615384614,2.8953846153846152,3.1292307692307695,3.363076923076923,3.596923076923077,3.8307692307692305,4.064615384615385,4.298461538461538,4.532307692307692,4.766153846153847,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >